NYSE: BTI$ 30.265(0.348)
To build A Better Tomorrow™, we must reduce the health impact of our business. We do this by investing in and innovating our New Category products, offering a greater choice of potentially reduced-risk products for adult tobacco consumers.
THR is one of the greatest public health opportunities we have worldwide because it is about reduced risk to the individual adult smoker and impact on the community and society.
-Priscilla Samuel, PhD, Executive Vice President of Scientific Research & Development
We believe a world without harm reduction options does more harm. Last year, we presented dedicated Tobacco Harm Reduction efforts at key industry forums. This included a website which provides an educational overview of THR, identifies key scientific studies, and demonstrates the need for collective action.
THR is an evidence-based public health strategy intended to lower the health risks associated with using combustible tobacco products.
In May 2022, the U.S. Food and Drug Administration (FDA) issued Marketing Granted Orders for several of our Vuse Vibe and Vuse Ciro products, building on the prior Marketing Authorizations granted by FDA in October 2021 for Vuse Solo products in Original flavor. These authorizations mean the FDA has determined that the marketing of these vapor products is appropriate for the protection of public health, and they are able to remain on the U.S. market.
Our organization’s continued focus on science and innovation has supported these robust PMTA submissions which have enabled FDA to evaluate and provide marketing authorizations for these products.
With these Market Authorizations through Premarket Tobacco Product Applications (PMTA) process, we have the broadest portfolio of authorizations provided to any organization in the U.S. to date.
Vuse Alto's PMTA remains under review and Vuse Alto remains available for adult nicotine consumers.
This is an important milestone on our transformation journey and demonstrates continued momentum as we work together to build A Better Tomorrow™ by reducing the health impact of our business.
The annual Global Tobacco & Nicotine Forum in Washington, DC, has been a global exchange of views since it was founded in 2008. It attracts high-profile scientists, public health experts, government officials and investors. In 2022, our colleagues participated in several panel events, speeches and engagements focused on Tobacco Harm Reduction.
EVP, Scientific Research and Development
VP, Scientific and Regulatory Affairs
SVP, Business Communications and Sustainability
At Reynolds, we put science first, focusing our research efforts on potentially reduced-risk products as we accelerate our Tobacco Harm Reduction efforts to reduce the health impact of our business.
World-class science is crucial to providing a robust evidence base to substantiate the role of New Category products in Tobacco Harm Reduction. In September, 15 Reynolds scientists presented their scientific research at the 75th Tobacco Science Research Conference (TSRC) in New Orleans, L.A.
Science brings a wealth of information to help transform the industry. We have the potential to impact the future products for the organization as well as provide the science to support those products in the context of regulatory reviews and applications.
-Sarah Baxter-Wright, PhD, Head of Global Pre-Clinical Sciences
The FDA states that tobacco product categories containing nicotine pose different degrees of health risks to the consumer, referred to as the continuum of risk.* Combustible products, or products that burn tobacco, are the riskiest, and other products, such as tobacco heating products, nicotine pouches, and e-cigarettes present potentially lower levels of risk. Adult smokers who are uninterested in quitting tobacco products altogether have the option to migrate to potentially reduced-risk product categories.
Electronic Nicotine Delivery Systems (ENDS), commonly known as vaping products, are battery-powered devices that heat e-liquid to produce an inhalable aerosol. E-liquid is drawn into the wick from a reservoir or tank and is then heated to form an aerosol when the consumer puffs on the product. The atomizer – the part that produces the vapor – consists of a tiny electric heater combined with a wick made from absorbent materials such as glass fiber, cotton, or ceramic. E-liquids either contain nicotine derived from tobacco or synthetic nicotine.
Nicotine pouches, often referred to as modern oral products, are smokeless, oral, tobacco leaf-free pouches that are placed between the gum and the lip to provide nicotine for absorption through the oral mucosa. The nicotine is often derived from tobacco and does not contain tobacco leaf. Adult nicotine consumers place the disposable pouch between their gum and lip during which nicotine and flavors are released.
Traditional oral products — also known as smokeless tobacco products — are those containing tobacco leaf and include portioned snus, loose moist, and portioned moist oral tobacco products, among others. Different from modern oral nicotine pouches, these pouches contain tobacco leaf. However, there is no combustion when using these products.
Tobacco heating products (THP) are products in which tobacco is heated and not burned to release nicotine and generate an aerosol. The burning of a normal cigarette can reach over 900°C, but the heating chamber in an electronic THP heating chamber device reaches up to 260°C, which is not a high enough temperature to create combustion. The lower temperature can result in lower yields of harmful and potentially harmful constituents compared to combustible cigarette smoke.
Learn more about how our ESG framework is driven by our purpose to deliver A Better Tomorrow™
